Mesoblast's Inclusion in the S&P/ASX 200 Index
Mesoblast Limited (NASDAQ: MESO), recognized as a pioneering force in allogeneic cellular medicines targeted at inflammatory diseases, proudly announces its addition to the esteemed S&P/ASX 200 Index. This significant step, effective from early March, is a testament to the company's growth and evolving market presence.
Understanding the S&P/ASX 200 Index
The S&P/ASX 200 Index is a crucial benchmark for institutional investors in Australia, comprising 200 top stocks listed on the Australian Stock Exchange (ASX), selected based on float-adjusted market capitalization. It serves as an essential gauge of the Australian equities market, providing insight into the performance of formidable companies.
About Mesoblast and Its Innovative Solutions
Mesoblast stands at the forefront of developing cutting-edge cellular therapies to combat severe inflammatory conditions. By harnessing its unique mesenchymal lineage cell therapy technology, Mesoblast aims to mitigate the severe impacts of inflammation through its specialized treatment modalities. The company’s flagship product, RYONCIL (remestemcel-L), stands as the first FDA-approved mesenchymal stromal cell therapy addressing steroid-refractory acute graft versus host disease in pediatric patients.
Future Developments and Commitment to Innovation
Looking ahead, Mesoblast is committed to expanding its range of therapies. The company is developing RYONCIL for adult indications and focusing on other inflammatory diseases such as biologic-resistant inflammatory bowel disease. Additionally, rexlemestrocel-L is part of the pipeline targeting heart failure and chronic low back pain. These efforts reflect Mesoblast’s ambitious strategy to leverage its technological advancements in various medical applications.
Robust Intellectual Property Framework
Mesoblast has established an impressive global intellectual property portfolio comprising over 1,000 granted patents and applications. This portfolio guarantees commercial protection up until at least 2041, enabling the company to sustain its competitive edge and continue its innovative endeavors in cellular medicines.
Manufacturing Excellence at Mesoblast
Utilizing proprietary manufacturing processes, Mesoblast produces scalable, off-the-shelf cellular medicines that comply with defined pharmaceutical release criteria. This ensures the potential availability of their therapies to patients across the globe, enhancing accessibility and treatment options.
Company Contact Information
For inquiries, Mesoblast provides accessible contact points for both corporate communications and media relations. Investors can reach out to Paul Hughes at investors@mesoblast.com, while media inquiries can be directed to Allison Worldwide at +1 603 545 4843 or Emma Neal at emma.neal@allisonworldwide.com.
Frequently Asked Questions
What is Mesoblast known for?
Mesoblast is renowned for its development of allogeneic cellular medicines designed to treat severe inflammatory conditions.
When did Mesoblast join the S&P/ASX 200 Index?
Mesoblast was added to the S&P/ASX 200 Index effective from March 6, showcasing its growth and significance in the market.
What is RYONCIL?
RYONCIL (remestemcel-L) is Mesoblast's FDA-approved therapy for treating steroid-refractory acute graft versus host disease in children aged two months and older.
What future therapies is Mesoblast developing?
Mesoblast is advancing therapies for adult SR-aGvHD, inflammatory bowel disease, heart failure, and chronic low back pain.
How can stakeholders contact Mesoblast?
Stakeholders can contact Mesoblast for inquiries through dedicated email addresses for investor relations and media contacts.
